Yeksan M, Türk S, Polat M, Ciğli A, Erdoğan Y
Department of Nephrology, University Hospital, Konya, Turkey.
Int J Artif Organs. 1992 Dec;15(12):704-7.
The aim of this study was to evaluate the effect of 1,25 (OH)2D3 treatment on lipid levels in uremic hemodialysis (HD) patients. Thirty-one HD patients who had never been treated with vitamin D nor related drugs and 12 healthy subjects with normal renal functions were studied. Uremic HD patients were randomly divided into two groups. Sixteen uremic HD patients were treated with oral calcitriol (0.5 micrograms/day) for 8 weeks. 13 uremic HD patients and 12 healthy subjects were given placebo. In all these cases before and after 8 weeks of treatments; serum total lipid, total cholesterol, HDL-cholesterol, LDL-cholesterol and triglyceride levels were determined. After calcitriol treatment, triglyceride levels were significantly decreased. But total lipid, cholesterol, HDL-cholesterol and LDL-cholesterol levels did not significantly change. In the other two groups there were no significant changes. These results show that calcitriol treatment has a positive effect on triglyceride levels in uremic HD patients. This effect of mechanism of calcitriol treatment has not been known yet. But it could be due to regulation carbohydrates metabolism and normalization of parathormone (PTH) levels.
本研究的目的是评估1,25(OH)2D3治疗对尿毒症血液透析(HD)患者血脂水平的影响。研究了31例从未接受过维生素D或相关药物治疗的HD患者以及12例肾功能正常的健康受试者。尿毒症HD患者被随机分为两组。16例尿毒症HD患者接受口服骨化三醇(0.5微克/天)治疗8周。13例尿毒症HD患者和12例健康受试者给予安慰剂。在所有这些病例治疗8周前后,测定血清总脂质、总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇和甘油三酯水平。骨化三醇治疗后,甘油三酯水平显著降低。但总脂质、胆固醇、高密度脂蛋白胆固醇和低密度脂蛋白胆固醇水平无显著变化。在其他两组中也没有显著变化。这些结果表明,骨化三醇治疗对尿毒症HD患者的甘油三酯水平有积极影响。骨化三醇治疗的这种作用机制尚不清楚。但这可能是由于调节碳水化合物代谢和甲状旁腺激素(PTH)水平正常化所致。